A Simple Heliodon System for Horizontal Placed Models

Most probably, all our buildings are affected by sunlight. Hence, the ignorance of the sun's impact results in overheating, glare, and missed opportunities for the positive use of daylight, leading to wasted energy. Heliodon is considered to be a powerful tool that can aid students, professionals, building developers and users to better understand the relationship between the sun's path and its effects on the architectural model(s). Most of the heliodons are relatively expensive and complex in operation. Thus, the need to design and build a simple and relatively inexpensive one emerged. It was proposed to work on this heliodon as a team project in the environmental control class “fall-2016”. The authors put the design concept and introduced a mathematical calculations table to be used with the physical heliodon, while nine students participated in the manufacturing process. The design concept is based on determining the sun's position by converting the Altitude and Azimuth angels to their corresponding measurements on the (X, Y & Z) coordinates (in relation to the observer's location). One light source can be moved on a set of graded tubes assembled in the shape of a wire frame box (thus the X, Y & Z distances could be measured) to simulate the sun's position and its lighting conditions for any latitude, at any time for any chosen day

Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design

Although the treatment of relapsed/refractory multiple myeloma has improved dramatically over the past decade, the disease remains incurable; therefore, additional therapies are needed. Novel combination therapies incorporating monoclonal antibodies have shown significant promise. Here we describe the design of a Phase III study (NCT03275285, IKEMA), which is evaluating isatuximab plus carfilzomib and low-dose dexamethasone, versus carfilzomib/dexamethasone in relapsed/refractory multiple myeloma. The primary end point is progression-free survival. Responses are being determined by an independent review committee using 2016 International Myeloma Working Group criteria, and safety will be assessed throughout. The first patient was recruited in November 2017, and the last patient was recruited in March 2019; 302 patients have been randomized, and the study is ongoing. / Clinical trial registration: NCT0327528

Treatments for improving tree growth, yield and fruit quality and for reducing double fruit and deep suture incidence in “Desert red” peach trees

Five years old “Desert red” peach trees budded on Nemaguard rootstock and grown in sandy soil at commercial orchard Al-Nubariacity, El-Behira Governorate-Egypt were treated with some agricultural treatments involving thinning out pruning, fruit thinning and foliarapplication of potassium silicate (25% S +10% K2O) at 0.1% and super grow (20% N, 20% P2O5 and 20% K2O) at 0.3% in 2014 and 2015seasons, to study their effects on yield and fruit quality and the relationship between nutrient balance and yield of “Desert red” peach trees.Beside, testing the influence of used treatments on two physiological disorder, double fruit and deep suture %. Also, economic evaluationof different treatments was done. All obtained data were statistically analyzed using a randomized complete block design. Depending on theobtained results in this study, it could be concluded that application of thinning out pruning 35%, fruit thinning by leaving 15 cm betweenfruits on one-year old shoot at 20 days after full bloom and foliar application of potassium silicate which sprayed five times during eachgrowing season at fruit set, the second fruit development stage, the beginning of the fruit color change and twice after month from harvest,most profitable treatment for peach trees grown under conditions of this investigation. This treatment gave the best vegetative growth, yield,fruit quality, higher crop value with high net income /fed. from “Desert red” peach trees, in addition, reduced the percentage of double fruitand deep suture by more than 50% in both seasons, therefore, the study recommends this treatment for “Desert red” peach growers

Treatments for improving tree growth, yield and fruit quality and for reducing double fruit and deep suture incidence in “Desert red” peach trees

Five years old “Desert red” peach trees budded on Nemaguard rootstock and grown in sandy soil at commercial orchard Al-Nubaria city, El-Behira Governorate-Egypt were treated with some agricultural treatments involving thinning out pruning, fruit thinning and foliar application of potassium silicate (25% S +10% K2O) at 0.1% and super grow (20% N, 20% P2O5 and 20% K2O) at 0.3% in 2014 and 2015 seasons, to study their effects on yield and fruit quality and the relationship between nutrient balance and yield of “Desert red” peach trees. Beside, testing the influence of used treatments on two physiological disorder, double fruit and deep suture %. Also, economic evaluation of different treatments was done. All obtained data were statistically analyzed using a randomized complete block design. Depending on the obtained results in this study, it could be concluded that application of thinning out pruning 35%, fruit thinning by leaving 15 cm between fruits on one-year old shoot at 20 days after full bloom and foliar application of potassium silicate which sprayed five times during each growing season at fruit set, the second fruit development stage, the beginning of the fruit color change and twice after month from harvest, most profitable treatment for peach trees grown under conditions of this investigation. This treatment gave the best vegetative growth, yield, fruit quality, higher crop value with high net income /fed. from “Desert red” peach trees, in addition, reduced the percentage of double fruit and deep suture by more than 50% in both seasons, therefore, the study recommends this treatment for “Desert red” peach growers

Development of polyvinyl alcohol nanofiber scaffolds loaded with flaxseed extract for bone regeneration: phytochemicals, cell proliferation, adhesion, and osteogenic gene expression

Introduction: Bone tissue engineering seeks innovative materials that support cell growth and regeneration. Electrospun nanofibers, with their high surface area and tunable properties, serve as promising scaffolds. This study explores the incorporation of flaxseed extract, rich in polyphenolic compounds, into polyvinyl alcohol (PVA) nanofibers to improve their application in bone tissue engineering.Methods: High-performance liquid chromatography (HPLC) identified ten key compounds in flaxseed extract, including polyphenolic acids and flavonoids. PVA nanofibers were fabricated with 30 wt.% flaxseed extract (P70/E30) via electrospinning. We optimized characteristics like diameter, hydrophilicity, swelling behavior, and hydrolytic degradation. MG-63 osteoblast cultures were used to assess scaffold efficacy through cell adhesion, proliferation, viability (MTT assay), and differentiation. RT-qPCR measured expression of osteogenic genes RUNX2, COL1A1, and OCN.Results: Flaxseed extract increased nanofiber diameter from 252 nm (pure PVA) to 435 nm (P70/E30). P70/E30 nanofibers showed higher cell viability (102.6% vs. 74.5% for pure PVA), although adhesion decreased (151 vs. 206 cells/section). Notably, P70/E30 enhanced osteoblast differentiation, significantly upregulating RUNX2, COL1A1, and OCN genes.Discussion: Flaxseed extract incorporation into PVA nanofibers enhances bone tissue engineering by boosting osteoblast proliferation and differentiation, despite reduced adhesion. These properties suggest P70/E30’s potential for regenerative medicine, emphasizing scaffold optimization for biomedical applications

Amenability of groups and GG-sets

This text surveys classical and recent results in the field of amenability of groups, from a combinatorial standpoint. It has served as the support of courses at the University of G\"ottingen and the \'Ecole Normale Sup\'erieure. The goals of the text are (1) to be as self-contained as possible, so as to serve as a good introduction for newcomers to the field; (2) to stress the use of combinatorial tools, in collaboration with functional analysis, probability etc., with discrete groups in focus; (3) to consider from the beginning the more general notion of amenable actions; (4) to describe recent classes of examples, and in particular groups acting on Cantor sets and topological full groups

New insights into the kinetics and variability of egg excretion in controlled human hookworm infections

Four healthy volunteers were infected with 50 Necator americanus infective larvae (L3) in a controlled human hookworm infection trial and followed for 52 weeks. The kinetics of fecal egg counts in volunteers was assessed with Bayesian multilevel analysis, which revealed an increase between weeks 7 and 13, followed by an egg density plateau of about 1000 eggs/g of feces. Variation in egg counts was minimal between same-day measurements but varied considerably between days, particularly during the plateau phase. These analyses pave the way for the controlled human hookworm model to accelerate drug and vaccine efficacy studies

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

Treatment options in multiple myeloma (MM) are increasing with the introduction of complex multi-novel-agent-based regimens investigated in randomized clinical trials. However, application in the real-world setting, including feasibility of and adherence to these regimens, may be limited due to varying patient-, treatment-, and disease-related factors. Furthermore, approximately 40% of real-world MM patients do not meet the criteria for phase 3 studies on which approvals are based, resulting in a lack of representative phase 3 data for these patients. Therefore, treatment decisions must be tailored based on additional considerations beyond clinical trial efficacy and safety, such as treatment feasibility (including frequency of clinic/hospital attendance), tolerability, effects on quality of life (QoL), and impact of comorbidities. There are multiple factors of importance to real-world MM patients, including disease symptoms, treatment burden and toxicities, ability to participate in daily activities, financial burden, access to treatment and treatment centers, and convenience of treatment. All of these factors are drivers of QoL and treatment satisfaction/compliance. Importantly, given the heterogeneity of MM, individual patients may have different perspectives regarding the most relevant considerations and goals of their treatment. Patient perspectives/goals may also change as they move through their treatment course. Thus, the ‘efficacy’ of treatment means different things to different patients, and treatment decision-making in the context of personalized medicine must be guided by an individual’s composite definition of what constitutes the best treatment choice. This review summarizes the various factors of importance and practical issues that must be considered when determining real-world treatment choices. It assesses the current instruments, methodologies, and recent initiatives for analyzing the MM patient experience. Finally, it suggests options for enhancing data collection on patients and treatments to provide a more holistic definition of the effectiveness of a regimen in the real-world setting

Chemoreception Regulates Chemical Access to Mouse Vomeronasal Organ: Role of Solitary Chemosensory Cells

Controlling stimulus access to sensory organs allows animals to optimize sensory reception and prevent damage. The vomeronasal organ (VNO) detects pheromones and other semiochemicals to regulate innate social and sexual behaviors. This semiochemical detection generally requires the VNO to draw in chemical fluids, such as bodily secretions, which are complex in composition and can be contaminated. Little is known about whether and how chemical constituents are monitored to regulate the fluid access to the VNO. Using transgenic mice and immunolabeling, we found that solitary chemosensory cells (SCCs) reside densely at the entrance duct of the VNO. In this region, most of the intraepithelial trigeminal fibers innervate the SCCs, indicating that SCCs relay sensory information onto the trigeminal fibers. These SCCs express transient receptor potential channel M5 (TRPM5) and the phospholipase C (PLC) β2 signaling pathway. Additionally, the SCCs express choline acetyltransferase (ChAT) and vesicular acetylcholine transporter (VAChT) for synthesizing and packaging acetylcholine, a potential transmitter. In intracellular Ca2+ imaging, the SCCs responded to various chemical stimuli including high concentrations of odorants and bitter compounds. The responses were suppressed significantly by a PLC inhibitor, suggesting involvement of the PLC pathway. Further, we developed a quantitative dye assay to show that the amount of stimulus fluid that entered the VNOs of behaving mice is inversely correlated to the concentration of odorous and bitter substances in the fluid. Genetic knockout and pharmacological inhibition of TRPM5 resulted in larger amounts of bitter compounds entering the VNOs. Our data uncovered that chemoreception of fluid constituents regulates chemical access to the VNO and plays an important role in limiting the access of non-specific irritating and harmful substances. Our results also provide new insight into the emerging role of SCCs in chemoreception and regulation of physiological actions

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes